Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Archives of Pathology & Laboratory Medicine|March 2, 2005
Malignant deciduoid mesothelioma: a diagnostic challengeNajat Mourra, Cecile de Chaisemartin, Isabelle Goubin-Versini, et al.International Journal of Cancer|December 18, 2009
Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agentsNicolas Goasguen, Cecile de Chaisemartin, Antoine Brouquet, et al.Brachytherapy|September 14, 2019
High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancersLeonel Varela Cagetti, Christophe Zemmour, Naji Salem, et al.International Journal of Radiation Oncology, Biology, Physics|November 25, 2010
Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancerLaurence Moureau-Zabotto, Bertrand Farnault, Cecile de Chaisemartin, et al.Brachytherapy|May 7, 2023
The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatmentsLeonel Varela Cagetti, Laurence Moureau-Zabotto, Christophe Zemmour, et al.Journal of Contemporary Brachytherapy|June 3, 2026
Chemoradiotherapy for anal canal cancers: Does the choice of boost technique matter?Leonel Varela Cagetti, Julia Gilhodes, Marjorie Ferré, et al.Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|February 13, 2021
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trialMehdi Karoui, Claire Gallois, Guillaume Piessen, et al.The Lancet. Gastroenterology & Hepatology|February 12, 2020
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trialEric Rullier, Véronique Vendrely, Julien Asselineau, et al.Pageof 1